VALNEVA SE (VLA.PA) Stock Fundamental Analysis
Europe - EPA:VLA - FR0004056851 - Common Stock
3.72 EUR
+0.06 (+1.69%)
We assign a fundamental rating of 3 out of 10 to VLA. VLA was compared to 74 industry peers in the Biotechnology industry. Both the profitability and financial health of VLA have multiple concerns. VLA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year VLA has reported negative net income.
VLA had a negative operating cash flow in the past year.
VLA had negative earnings in each of the past 5 years.
In multiple years VLA reported negative operating cash flow during the last 5 years.
1.2 Ratios
VLA's Return On Assets of -18.09% is in line compared to the rest of the industry. VLA outperforms 56.76% of its industry peers.
VLA has a Return On Equity (-45.87%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROIC | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 48.94%, VLA is in line with its industry, outperforming 50.00% of the companies in the same industry.
VLA's Gross Margin has declined in the last couple of years.
VLA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
2. Health
2.1 Basic Checks
VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VLA has been increased compared to 1 year ago.
The number of shares outstanding for VLA has been increased compared to 5 years ago.
VLA has a better debt/assets ratio than last year.
2.2 Solvency
VLA has an Altman-Z score of -0.29. This is a bad value and indicates that VLA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.29, VLA perfoms like the industry average, outperforming 45.95% of the companies in the same industry.
A Debt/Equity ratio of 0.80 indicates that VLA is somewhat dependend on debt financing.
VLA's Debt to Equity ratio of 0.80 is in line compared to the rest of the industry. VLA outperforms 43.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.29 |
ROIC/WACCN/A
WACC7.98%
2.3 Liquidity
A Current Ratio of 2.27 indicates that VLA has no problem at all paying its short term obligations.
VLA's Current ratio of 2.27 is in line compared to the rest of the industry. VLA outperforms 51.35% of its industry peers.
VLA has a Quick Ratio of 1.77. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
VLA has a Quick ratio (1.77) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
The earnings per share for VLA have decreased strongly by -95.65% in the last year.
Looking at the last year, VLA shows a very strong growth in Revenue. The Revenue has grown by 31.49%.
The Revenue has been growing slightly by 6.09% on average over the past years.
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%
3.2 Future
VLA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 70.29% yearly.
Based on estimates for the next years, VLA will show a very strong growth in Revenue. The Revenue will grow by 21.39% on average per year.
EPS Next Y-619.37%
EPS Next 2Y-118.68%
EPS Next 3Y110.39%
EPS Next 5Y70.29%
Revenue Next Year-3.79%
Revenue Next 2Y3.74%
Revenue Next 3Y28.13%
Revenue Next 5Y21.39%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VLA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VLA's earnings are expected to grow with 110.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-118.68%
EPS Next 3Y110.39%
5. Dividend
5.1 Amount
No dividends for VLA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:VLA (11/10/2025, 7:00:00 PM)
3.72
+0.06 (+1.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.62%
Inst Owner ChangeN/A
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap319.61M
Revenue(TTM)291.38M
Net Income(TTM)-85.51M
Analysts81.82
Price Target7.17 (92.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.78%
Min EPS beat(2)56.68%
Max EPS beat(2)62.87%
EPS beat(4)3
Avg EPS beat(4)14.13%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)-23.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.69%
Min Revenue beat(2)16.4%
Max Revenue beat(2)26.97%
Revenue beat(4)3
Avg Revenue beat(4)10.09%
Min Revenue beat(4)-4.78%
Max Revenue beat(4)26.97%
Revenue beat(8)4
Avg Revenue beat(8)1.3%
Revenue beat(12)7
Avg Revenue beat(12)19.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.48%
PT rev (3m)-6.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.9%
EPS NY rev (1m)-5.7%
EPS NY rev (3m)-3.15%
Revenue NQ rev (1m)-7.89%
Revenue NQ rev (3m)-11.9%
Revenue NY rev (1m)-7.63%
Revenue NY rev (3m)-9.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.71 | ||
| P/tB | 1.97 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS3.39
BVpS2.17
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% | ||
| FCFM | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 71.71% | ||
| Cap/Sales | 5.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 | ||
| Altman-Z | -0.29 |
F-Score4
WACC7.98%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y-619.37%
EPS Next 2Y-118.68%
EPS Next 3Y110.39%
EPS Next 5Y70.29%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%
Revenue Next Year-3.79%
Revenue Next 2Y3.74%
Revenue Next 3Y28.13%
Revenue Next 5Y21.39%
EBIT growth 1Y-49.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-280.12%
EBIT Next 3Y59.13%
EBIT Next 5Y30.38%
FCF growth 1Y88.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.27%
OCF growth 3YN/A
OCF growth 5YN/A
VALNEVA SE / VLA.PA FAQ
Can you provide the ChartMill fundamental rating for VALNEVA SE?
ChartMill assigns a fundamental rating of 3 / 10 to VLA.PA.
What is the valuation status of VALNEVA SE (VLA.PA) stock?
ChartMill assigns a valuation rating of 1 / 10 to VALNEVA SE (VLA.PA). This can be considered as Overvalued.
Can you provide the profitability details for VALNEVA SE?
VALNEVA SE (VLA.PA) has a profitability rating of 1 / 10.
Can you provide the financial health for VLA stock?
The financial health rating of VALNEVA SE (VLA.PA) is 3 / 10.